View More View Less
  • 1 Debreceni Egyetem, Általános Orvostudományi Kar, Debrecen
  • 2 Debreceni Egyetem, Általános Orvostudományi Kar, Debrecen
  • 3 Debreceni Egyetem, Általános Orvostudományi Kar, Debrecen, Nagyerdei krt. 98., 4032
  • 4 Jósa András Oktató Kórház, Nyíregyháza
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Absztrakt:

Az évtizedek óta várt új orális antikoagulánsok (NOAC) egyre bővülő körben alkalmazott gyógyszerekké váltak a terápiában, hiszen az orális antikoagulánsként korábban egyedüliként alkalmazott kumarinszármazékokhoz képest számos klinikai indikációban a kumarinokkal azonos vagy annál jobb klinikai hatékonyságot mutatnak. Ennek következtében a direkt trombininhibitor dabigatran, majd a direkt X-es alvadási faktort gátló szerek (rivaroxaban, apixaban, edoxaban) az elmúlt években a napi terápiás gyakorlat részévé váltak. Elterjedésüket nem kis részben segítette azon ajánlás, hogy nem igényelnek laboratóriumi monitorizálást, ami mind a beteg, mind a kezelőorvos számára rendkívül nagy előnyt jelent. Az elmúlt évek tapasztalatai azonban bebizonyították, hogy a ‘one size fits all’ szemlélet erősen szimplifikált a NOAC-terápia során, és számos olyan eset van, amikor ezen gyógyszerek koncentrációjának monitorizálása elkerülhetetlen vagy erősen ajánlott. Ez az összefoglaló tanulmány a NOAC-kezelés laboratóriumi vonzatait tárgyalja, kiemelten a hemosztázis alap- és speciális tesztjeire való hatásukat, valamint a korrekt NOAC-koncentráció meghatározására szolgáló laboratóriumi módszereket. Orv Hetil. 2017; 158(49): 1930–1945.

  • 1

    McLean J. The thromboplastic action of cephalin. Am J Physiol. 1916; 41: 250.

  • 2

    Howell WH, Holt E. Two new factors in blood coagulation – heparin and proantithrombin. Am J Physiol. 1918; 47: 328–341.

  • 3

    Campbell HA, Link KP. Studies on the hemorrhagic sweet clover disease IV. The isolation and crystallization of the hemorrhagic agent. J Biol Chem. 1941; 138: 21–33.

  • 4

    Boda Z. Novel strategies in anticoagulant therapy. In: Boda Z. (ed.) Venous thromboembolism – Anticoagulant therapy. [Új stratégiák az antikoaguláns terápiában. In: Boda Z. (szerk.) Vénás tromboembóliák – antikoaguláns terápia.] Medicina Könyvkiadó, Budapest, 2014; pp. 301–325. [Hunarian]

  • 5

    Eriksson BI, Dahl OE, Rosencher N, et al. For the RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949–956.

  • 6

    Eriksson BE, Dahl OE, Huo MH, et al. For the RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). Thromb Haemost. 2011; 105: 721–729.

  • 7

    Eriksson BI, Dahl OE, Rosencher N, et al. For the RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007; 5: 2178–2185.

  • 8

    Lassen MR, Gallus A, Raskob GE, et al. For the ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010; 363: 2487–2498.

  • 9

    Lassen MR, Raskob GE, Gallus A, et al. The ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807–815.

  • 10

    Eriksson BI, Borris LC, Friedman RJ, et al. For the RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358: 2765–2775.

  • 11

    Lassen MR, Ageno W, Borris LC, et al. For the RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358: 2776–2786.

  • 12

    Chai-Adisaksopha C, Crowther M, Isayama T, et al. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014; 124: 2450–2458.

  • 13

    Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol. 2017; 23: 1954–1963.

  • 14

    Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131: 157–164.

  • 15

    Tamayo S, Frank Peacock W, Patel M, et al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol. 2015; 38: 63–68.

  • 16

    Riley TR, Gauthier-Lewis ML, Sanchez CK, et al. Role of agents for reversing the effects of target-specific oral anticoagulants. Am J Health Syst Pharm. 2017; 74: 54–61.

  • 17

    Boda Z. Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice. [Teendők súlyos vérzés vagy sürgős sebészeti beavatkozás esetén direkt orális antikoaguláns gyógyszerrel kezeltekben. Az új dabigatran-antidótum: idarucizumab helye a klinikai gyakorlatban.] Orv Hetil. 2016; 157: 443–450. [Hungarian]

  • 18

    Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149: 315–352.

  • 19

    Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37: 2893–2962.

  • 20

    Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014; 35: 3033–3069.

  • 21

    Eikelboom JW, Connolly SJ, Brueckmann M, et al. For the RE-ALIGN investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013; 369: 1206–1214.

  • 22

    Beyer-Westendorf J, Marten S, Michalski F. Outcome of NOAC exposure during pregnancy (...and the problem of event reporting...). Blood 2015; 126: 1125.

  • 23

    Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res. 2011; 127(Suppl 2): 5S–12S.

  • 24

    Eisert WG, Hauel N, Stangier J, et al. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol. 2010; 30: 1885–1889.

  • 25

    Stangier, J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008; 47: 285–295.

  • 26

    Driesz L, Barabás E, Bodócs I, et al. The first use of iv. idarucizumab for dabigatran reversal in Hungary. [A dabigatran-antidótum, az intravénás idarucizumab első hazai alkalmazása.] Orv Hetil. 2017; 158: 387–392. [Hungarian]

  • 27

    Perzborn E, Roehrig S, Straub A, et al. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol. 2010; 30: 376–381.

  • 28

    Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009; 37: 74–81.

  • 29

    Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010; 50: 743–753.

  • 30

    Thoenes M, Minguet J, Bramlage K, et al. Betrixaban – the next direct factor Xa inhibitor? Expert Rev Hematol. 2016; 9: 1111–1117.

  • 31

    European Medicines Agency. Xarelto – Summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf

  • 32

    European Medicines Agency. Pradaxa – Summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000829/WC500041060.pdf

  • 33

    European Medicines Agency. Eliquis – Summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf

  • 34

    European Medicines Agency. Lixiana – Summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002629/WC500189048.pdf

  • 35

    Salmonson T, Dogne JM, Janssen H, et al. Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future. Views from a workshop at the European Medicines Agency (EMA). Eur Heart J Cardiovasc Pharmacother. 2017; 3: 42–47.

  • 36

    Mismetti P, Laporte S. New oral antithrombotics: a need for laboratory monitoring. For. J Thromb Haemost. 2010; 8: 621–626.

  • 37

    Ten Cate H. Monitoring new oral anticoagulants, managing thrombosis, or both? Thromb Haemost. 2012; 107: 803–805.

  • 38

    Ten Cate H. New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J. 2013; 11: 8.

  • 39

    Douxfils J, Gosselin RC. Laboratory assessment of direct oral anticoagulants. Semin Thromb Hemost. 2017; 43: 277–290.

  • 40

    Gosselin RC, Adcock DM. The laboratory’s 2015 perspective on direct oral anticoagulant testing. J Thromb Haemost. 2016; 14: 886–893.

  • 41

    Samama MM, Guinet C, Le Flem L, et al. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. J Thromb Thrombolysis 2013; 35: 140–146.

  • 42

    Levy JH, Ageno W, Chan NC, et al. For the Subcommittee on Control of Anticoagulation. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016; 14: 623–627.

  • 43

    Testa S, Tripodi A, Legnani C, et al. For the START-Laboratory Register. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. Thromb Res. 2016; 137: 178–183.

  • 44

    Lippi G, Favaloro EJ. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? Clin Chem Lab Med. 2015; 53: 185–197.

  • 45

    Reiffel JA, Weitz JI, Reilly P, et al. Cardiac Safety Research Consortium presenters and participants. NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. Am Heart J. 2016; 177: 74–86.

  • 46

    Samuelson BT, Cuker A. Measurement and reversal of the direct oral anticoagulants. Blood Rev. 2017; 31: 77–84.

  • 47

    Schmitz EM, Boonen K, van den Heuvel DJ, et al. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography – tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost. 2014; 12: 1636–1646.

  • 48

    Gous T, Couchman L, Patel JP, et al. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Ther Drug Monit. 2014; 36: 597–605.

  • 49

    Rohde G. Determination of rivaroxaban – a novel, oral, direct factor Xa inhibitor – in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 872: 43–50.

  • 50

    Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012; 107: 985–997.

  • 51

    Douxfils J, Dogné JM, Mullier F, et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost. 2013; 110: 543–549.

  • 52

    Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23: 138–143.

  • 53

    Gosselin RC, Dwyre DM, Dager WE. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann Pharmacother. 2013; 47: 1635–1640.

  • 54

    Brunetti L, Sanchez-Catanese B, Kagan L, et al. Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting. Thromb J. 2016; 14: 10.

  • 55

    Barrett YC, Wang Z, Frost C, et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010; 104: 1263–1271.

  • 56

    Harenberg J, Marx S, Weiss C, et al. Subcommittee on Control of Anticoagulation of the ISTH. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost. 2012; 10: 1433–1436.

  • 57

    Samama MM, Contant G, Spiro TE, et al. For the Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 2012; 107: 379–387.

  • 58

    Gouin-Thibault I, Flaujac C, Delavenne X, et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost. 2014; 111: 240–248.

  • 59

    Douxfils J, Chatelain C, Chatelain B, et al. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost. 2013; 110: 283–294.

  • 60

    Douxfils J, Chatelain B, Chatelain C, et al. Edoxaban: impact on routine and specific coagulation assays. A practical laboratory guide. Thromb Haemost. 2016; 115: 368–381.

  • 61

    Douxfils J, Tamigniau A, Chatelain B, et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost. 2013; 110: 723–731.

  • 62

    Harenberg J, Du S, Wehling M, et al. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study. Clin Chem Lab Med. 2016; 54: 275–283.

  • 63

    Dias JD, Norem K, Doorneweerd DD, et al. Use of thromboelastography (TEG) for detection of new oral anticoagulants. Arch Pathol Lab Med. 2015; 139: 665–673.

  • 64

    Herrmann R, Thom J, Wood A, et al. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost. 2014; 111: 989–995.

  • 65

    Adelmann D, Wiegele M, Wohlgemuth RK, et al. Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry. Thromb Res. 2014; 134: 918–923.

  • 66

    Chojnowski K, Górski T, Robak M, et al. Effects of rivaroxaban therapy on ROTEM coagulation parameters in patients with venous thromboembolism. Adv Clin Exp Med. 2015; 24: 995–1000.

  • 67

    Helin TA, Lemponen M, Hjemdahl P, et al. From laboratory to clinical practice: dabigatran effects on thrombin generation and coagulation in patient samples. Thromb Res. 2015; 136: 154–160.

  • 68

    Adcock DM, Gosselin R. Direct oral anticoagulants (DOACs) in the laboratory: 2015 Review. Thromb Res. 2015; 136: 7–12.

  • 69

    Kitchen S, Gray E, Mackie I, et al. On behalf of the BCSH committee. Measurement of non-coumarin anticoagulants and their effects on tests of haemostasis: Guidance from the British Committee for Standards in Haematology. Br J Haematol. 2014; 166: 830–841.

  • 70

    Hawes EM, Deal AM, Funk-Adcock D, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross sectional pharmacodynamics study based on peak and trough levels. J Thromb Haemost. 2013; 11: 1493–1502.

  • 71

    Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate – a novel reversible oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103: 1116–1127.

  • 72

    Dager WE, Gosselin RC, Kitchen S, et al. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother. 2012; 46: 1627–1636.

  • 73

    Lim MS, Chapman K, Swanepoel P, et al. Sensitivity of routine coagulation assays to direct oral anticoagulants: patient samples versus commercial drug-specific calibrators. Pathology 2016; 48: 712–719.

  • 74

    Van Veen JJ, Smith J, Kitchen S, et al. Normal prothrombin time in the presence of therapeutic levels of rivaroxaban. Br J Haematol. 2013; 160: 859–861.

  • 75

    Rodgers R, Bagot CN, Lawrence C, et al. Correlating prothrombin time with plasma rivaroxaban level. Br J Haematol. 2013; 163: 685–687.

  • 76

    Harenberg J, Marx S, Krämer R, et al. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Blood Coagul Fibrinolysis 2011; 22: 637–641.

  • 77

    Tripodi A, Chantarangkul V, Guinet C, et al. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost. 2011; 9: 226–228.

  • 78

    Francart S, Hawes EM, Deal A, et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost. 2014; 111: 1133–1140.

  • 79

    Eby C. Novel anticoagulants and laboratory testing. Int J Lab Hematol. 2013; 35: 262–268.

  • 80

    Bonar R, Favaloro EJ, Mohammed S, et al. The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 2015; 47: 355–364.

  • 81

    Mani H, Hesse C, Stratmann G, et al. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost. 2013; 109: 127–136.

  • 82

    Adcock DM, Gosselin R, Kitchen S, et al. The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol. 2013; 139: 102–109.

  • 83

    Ratzinger F, Lang M, Belik S, et al. Lupus-anticoagulant testing at NOAC trough levels. Thromb Haemost. 2016; 116: 235–240.

  • 84

    Favaloro EJ, Lippi G. Laboratory testing in the era of direct or non-vitamin K antagonist oral anticoagulants: A practical guide to measuring their activity and avoiding diagnostic errors. Semin Thromb Haemost. 2015; 41: 208–227.

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Sep 2020 18 1 2
Oct 2020 7 1 2
Nov 2020 18 2 0
Dec 2020 19 0 0
Jan 2021 27 0 0
Feb 2021 20 0 1
Mar 2021 0 0 0